Physician profile
Taylor Phillips
NPI 1063254589
$937.77
in general payments reported to CMS, 2019-2025
13 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $246 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.43 | 2024-2025 | Tezspire, Fasenra, Airsupra |
| Abbvie INC. | $153.51 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Dupixent |
| Dexcom, INC. | $60.30 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $37.96 | 2025 | Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $34.63 | 2024 | Opsumit |
| Abbott Laboratories | $24.61 | 2024 | Freestyle Libre 3 |
| Baxter Healthcare | $23.06 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Exact Sciences Corporation | $20.41 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $18.50 | 2024 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.84 | 2025 | Caplyta |
| Pfizer INC. | $16.70 | 2025 | |
| Merck Sharp & Dohme LLC | $14.83 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.